CY1115479T1 - Προφαρμακα 1'-υποκατεστημενου-καρβα-νουκλεοσιδιου για αντιιικη θεραπευτικη αγωγη - Google Patents
Προφαρμακα 1'-υποκατεστημενου-καρβα-νουκλεοσιδιου για αντιιικη θεραπευτικη αγωγηInfo
- Publication number
- CY1115479T1 CY1115479T1 CY20141100249T CY141100249T CY1115479T1 CY 1115479 T1 CY1115479 T1 CY 1115479T1 CY 20141100249 T CY20141100249 T CY 20141100249T CY 141100249 T CY141100249 T CY 141100249T CY 1115479 T1 CY1115479 T1 CY 1115479T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- substituted
- carbon
- nucleoside
- nucleoside products
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title abstract 3
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Δίδονται προφάρμακα φωσφορικού πυρρολο[1,2-f][1,2,4]τριαζιν-7-υλ νουκλεοσιδίου, όπου η 1 θέση του σακχάρου νουκλεοσιδίου είναι υποκατεστημένη με CN. Οι ενώσεις, συνθέσεις και μέθοδοι οι οποίες παρέχονται είναι χρήσιμες για τη θεραπευτική αγωγή μολύνσεων Ηπατίτιδας C.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34959710P | 2010-05-28 | 2010-05-28 | |
US35335110P | 2010-06-10 | 2010-06-10 | |
US36604110P | 2010-07-20 | 2010-07-20 | |
EP11725838.4A EP2576534B1 (en) | 2010-05-28 | 2011-05-26 | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
US13/117,060 US8415308B2 (en) | 2010-05-28 | 2011-05-26 | 1′-substituted-carba-nucleoside prodrugs for antiviral treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115479T1 true CY1115479T1 (el) | 2017-01-04 |
Family
ID=45375840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100249T CY1115479T1 (el) | 2010-05-28 | 2014-04-02 | Προφαρμακα 1'-υποκατεστημενου-καρβα-νουκλεοσιδιου για αντιιικη θεραπευτικη αγωγη |
Country Status (18)
Country | Link |
---|---|
US (1) | US8415308B2 (el) |
EP (1) | EP2576534B1 (el) |
JP (4) | JP5837577B2 (el) |
AR (1) | AR084389A1 (el) |
CY (1) | CY1115479T1 (el) |
DK (1) | DK2576534T3 (el) |
ES (1) | ES2465265T3 (el) |
HK (1) | HK1182387A1 (el) |
HR (1) | HRP20140370T1 (el) |
ME (1) | ME01882B (el) |
PL (1) | PL2576534T3 (el) |
PT (1) | PT2576534E (el) |
RS (1) | RS53244B (el) |
SI (1) | SI2576534T1 (el) |
SM (1) | SMT201400048B (el) |
TW (1) | TW201201815A (el) |
UY (1) | UY33414A (el) |
WO (1) | WO2011150288A1 (el) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
PT2268642E (pt) | 2008-04-23 | 2015-06-02 | Gilead Sciences Inc | Análogos de carba-nulceósidos 1¿-substituídos para tratamento antiviral |
CA2773773C (en) | 2009-09-21 | 2019-04-23 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
TW201201815A (en) * | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
JP5937073B2 (ja) | 2010-07-19 | 2016-06-22 | ギリード・サイエンシズ・インコーポレーテッド | ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法 |
AU2011280910B2 (en) | 2010-07-22 | 2015-07-09 | Gilead Sciences, Inc. | Methods and compounds for treating Paramyxoviridae virus infections |
US20130273005A1 (en) * | 2010-12-20 | 2013-10-17 | Gilead Sciences, Inc. | Methods for treating hcv |
US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013039920A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
NZ623396A (en) | 2011-09-16 | 2016-07-29 | Gilead Pharmasset Llc | Methods for treating hcv |
TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物 |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
AU2013266393B2 (en) * | 2012-05-22 | 2017-09-28 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
SG11201407336PA (en) | 2012-05-25 | 2015-03-30 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
GEP201706723B (en) | 2012-10-08 | 2017-08-25 | Idenix Pharmaceuticals Llk | 2'-chloro nucleoside analogs for hcv infection |
US9242988B2 (en) | 2012-10-17 | 2016-01-26 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2014059902A1 (en) * | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
LT2950786T (lt) | 2013-01-31 | 2020-03-10 | Gilead Pharmasset Llc | Dviejų antivirusinių junginių preparatų kompozicija |
WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
EP3004130B1 (en) | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
US10202411B2 (en) | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |
EP3137454A1 (en) | 2014-04-28 | 2017-03-08 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
TWI678369B (zh) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類 |
TWI673283B (zh) | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | 2’-氯胺基嘧啶酮及嘧啶二酮核苷類 |
TWI698444B (zh) * | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
KR20170123308A (ko) | 2014-12-26 | 2017-11-07 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
KR102363946B1 (ko) | 2015-03-06 | 2022-02-17 | 아테아 파마슈티컬즈, 인크. | HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드 |
CA2984421C (en) | 2015-05-01 | 2024-04-09 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
US9855289B2 (en) | 2015-08-05 | 2018-01-02 | Metro International Biotech, Llc | Nicotinamide mononucleotide derivatives and their uses |
PT3785717T (pt) | 2015-09-16 | 2022-04-14 | Gilead Sciences Inc | Métodos para o tratamento de infeções por coronaviridae |
SI3436461T1 (sl) | 2016-03-28 | 2024-03-29 | Incyte Corporation | Pirolotriazinske spojine kot tam-inhibitorji |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
KR20190043602A (ko) | 2016-09-07 | 2019-04-26 | 아테아 파마슈티컬즈, 인크. | Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드 |
US20190350960A1 (en) | 2017-01-04 | 2019-11-21 | President And Fellows Of Harvard College | Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same |
GEP20237457B (en) | 2017-02-01 | 2023-01-10 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for treatment of hepatitis c virus |
ES2961460T3 (es) | 2017-03-14 | 2024-03-12 | Gilead Sciences Inc | Métodos para tratar las infecciones por coronavirus felinas |
AR111490A1 (es) | 2017-05-01 | 2019-07-17 | Gilead Sciences Inc | Formas cristalinas de propanoato de (s)-2-etilbutil 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino) |
CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
BR122022008466B1 (pt) | 2017-12-07 | 2023-12-05 | Emory University | Uso de um composto |
TW202012001A (zh) | 2018-04-10 | 2020-04-01 | 美商亞堤製藥公司 | C型肝炎病毒(hcv)感染硬化之患者的治療 |
CA3163424A1 (en) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
CN113214262B (zh) * | 2020-02-05 | 2023-07-07 | 华创合成制药股份有限公司 | 一种含有胍基的化合物及其制备方法和用途 |
CN111320662B (zh) * | 2020-02-17 | 2022-11-25 | 南京医科大学 | 一类n-苄基取代的二脒那秦衍生物及其药物用途 |
TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
WO2021168004A1 (en) | 2020-02-18 | 2021-08-26 | Gilead Sciences, Inc. | Antiviral compounds |
TW202315607A (zh) * | 2020-02-18 | 2023-04-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
AU2021234308C1 (en) | 2020-03-12 | 2024-02-22 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
CN115362004A (zh) | 2020-04-06 | 2022-11-18 | 吉利德科学公司 | 1’-氰基取代的碳核苷类似物的吸入制剂 |
CN112778310A (zh) * | 2020-04-20 | 2021-05-11 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
JP2023528810A (ja) | 2020-05-29 | 2023-07-06 | ギリアード サイエンシーズ, インコーポレイテッド | レムデシビル治療方法 |
EP4172160A2 (en) * | 2020-06-24 | 2023-05-03 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
BR112023002951A2 (pt) | 2020-08-24 | 2023-03-21 | Gilead Sciences Inc | Compostos de fosfolipídio e usos destes |
TW202233204A (zh) | 2020-08-27 | 2022-09-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
TWI811812B (zh) * | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
WO2022166581A1 (zh) * | 2021-02-07 | 2022-08-11 | 石家庄迪斯凯威医药科技有限公司 | 一种核苷酸衍生物及其药物组合物和用途 |
US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
WO2001032153A2 (en) | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
NZ521210A (en) | 2000-02-18 | 2004-11-26 | Shire Biochem Inc | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
PT1411954E (pt) | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
MY134070A (en) | 2001-01-22 | 2007-11-30 | Isis Pharmaceuticals Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
JP2005536440A (ja) | 2001-09-28 | 2005-12-02 | イデニクス(ケイマン)リミテツド | 4’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物 |
WO2003100009A2 (en) | 2002-05-23 | 2003-12-04 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
WO2005123087A2 (en) * | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
JP2009504704A (ja) * | 2005-08-15 | 2009-02-05 | エフ.ホフマン−ラ ロシュ アーゲー | 抗ウイルス4′−置換プロヌクレオチドホスホルアミダート |
WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
WO2008005542A2 (en) * | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc., | Antiviral phosphinate compounds |
ES2390188T3 (es) | 2007-01-12 | 2012-11-07 | Biocryst Pharmaceuticals, Inc. | Análogos de nucleósidos antivirales |
DK2155758T3 (da) | 2007-05-10 | 2012-11-05 | Biocryst Pharm Inc | Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer |
TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
PT2268642E (pt) | 2008-04-23 | 2015-06-02 | Gilead Sciences Inc | Análogos de carba-nulceósidos 1¿-substituídos para tratamento antiviral |
UY31950A (es) * | 2008-07-01 | 2010-01-29 | Medivir Ab | Inhibidores de ciclopropil-polimerasa |
EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
CA2773773C (en) | 2009-09-21 | 2019-04-23 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
PE20210668A1 (es) * | 2009-09-21 | 2021-04-05 | Gilead Sciences Inc | Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
TW201201815A (en) * | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
-
2011
- 2011-05-25 TW TW100118301A patent/TW201201815A/zh unknown
- 2011-05-26 WO PCT/US2011/038253 patent/WO2011150288A1/en active Application Filing
- 2011-05-26 JP JP2013512264A patent/JP5837577B2/ja active Active
- 2011-05-26 ME MEP-2014-58A patent/ME01882B/me unknown
- 2011-05-26 EP EP11725838.4A patent/EP2576534B1/en active Active
- 2011-05-26 SI SI201130154T patent/SI2576534T1/sl unknown
- 2011-05-26 PL PL11725838T patent/PL2576534T3/pl unknown
- 2011-05-26 RS RS20140150A patent/RS53244B/en unknown
- 2011-05-26 ES ES11725838.4T patent/ES2465265T3/es active Active
- 2011-05-26 PT PT117258384T patent/PT2576534E/pt unknown
- 2011-05-26 US US13/117,060 patent/US8415308B2/en active Active
- 2011-05-26 DK DK11725838.4T patent/DK2576534T3/da active
- 2011-05-27 AR ARP110101821A patent/AR084389A1/es not_active Application Discontinuation
- 2011-05-27 UY UY0001033414A patent/UY33414A/es active IP Right Grant
-
2013
- 2013-08-20 HK HK13109734.7A patent/HK1182387A1/xx unknown
-
2014
- 2014-04-02 CY CY20141100249T patent/CY1115479T1/el unknown
- 2014-04-11 SM SM201400048T patent/SMT201400048B/xx unknown
- 2014-04-22 HR HRP20140370AT patent/HRP20140370T1/hr unknown
-
2015
- 2015-11-05 JP JP2015217492A patent/JP6193332B2/ja active Active
-
2017
- 2017-08-09 JP JP2017154096A patent/JP2018012706A/ja active Pending
-
2018
- 2018-06-06 JP JP2018108447A patent/JP2018162268A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1182387A1 (en) | 2013-11-29 |
RS53244B (en) | 2014-08-29 |
JP2018012706A (ja) | 2018-01-25 |
EP2576534B1 (en) | 2014-03-19 |
JP5837577B2 (ja) | 2015-12-24 |
ME01882B (me) | 2014-12-20 |
ES2465265T3 (es) | 2014-06-05 |
PL2576534T3 (pl) | 2014-07-31 |
EP2576534A1 (en) | 2013-04-10 |
HRP20140370T1 (hr) | 2014-05-23 |
JP6193332B2 (ja) | 2017-09-06 |
DK2576534T3 (da) | 2014-04-22 |
WO2011150288A1 (en) | 2011-12-01 |
UY33414A (es) | 2011-12-30 |
SMT201400048B (it) | 2014-05-07 |
JP2013528184A (ja) | 2013-07-08 |
JP2018162268A (ja) | 2018-10-18 |
US20120020921A1 (en) | 2012-01-26 |
US8415308B2 (en) | 2013-04-09 |
TW201201815A (en) | 2012-01-16 |
AR084389A1 (es) | 2013-05-15 |
PT2576534E (pt) | 2014-05-29 |
SI2576534T1 (sl) | 2014-06-30 |
JP2016094404A (ja) | 2016-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115479T1 (el) | Προφαρμακα 1'-υποκατεστημενου-καρβα-νουκλεοσιδιου για αντιιικη θεραπευτικη αγωγη | |
CY1118605T1 (el) | Αnαλογα 2'-φθορο υποκατεστημενου καρβα-νουκλεοζιδιου για αντι-ιικη θεραπεια | |
CY1121948T1 (el) | Πυρρολο [1,2,f][1,2,4]tpiazineς χρησιμες για θεραπεια λοιμωξεων αναπνευστικου συγκυτιακου ιου | |
CY1121468T1 (el) | Συνδυασμος παραγωγων πυρρολο[2,3-d]πυριμιδινης με εναν ή περισσοτερους επιπροσθετους παραγοντες ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak) | |
CY1119534T1 (el) | Παραγωγα φωσφορου ως αναστολεις κινασης | |
CY1126066T1 (el) | Υποκατεστημενα παραγωγα θειενο[2,3-d]πυριμιδινης ως αναστολεις της μενινης-mll και μεθοδοι χρησης | |
CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
CY1118239T1 (el) | Πυραζολο[1,5-α]πυριμιδινες και -τριαζινες ως αντι-ιικοι παραγοντες | |
CY1121460T1 (el) | Διαμορφωση του μεταγωγεα σηματος και του ενεργοποιητη εκφρασης της μεταγραφης 3 (stat3) | |
CY1120857T1 (el) | Jak1 αναστολεις για την αγωγη μυελοδυσπλαστικων συνδρομων | |
CY1119843T1 (el) | Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης | |
CY1123705T1 (el) | Αλατα και πολυμορφα μιας ενωσης τετρακυκλινης | |
CY1113647T1 (el) | Αναλογα καρβα-νουκλεοσιδιου για αντι-ιικη θεραπεια | |
CY1117743T1 (el) | Διυποκατεστημενα οκταϋδροπυρρολο [3,4-c]πυρρολια ως ρυθμιστες υποδοχεα ορεξινης | |
CY1115945T1 (el) | Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση | |
CR20110620A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus | |
SMT201300110B (it) | Processi intermedi per la preparazione di analoghidi 1'-cianocarbonucleoside | |
CY1117956T1 (el) | N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα | |
CY1111903T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση | |
UY36544A (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
CY1116383T1 (el) | Αντιβακτηριακες ενωσεις | |
CY1115107T1 (el) | ΕΝΩΣΕΙΣ ΥΠΟΚΑΤΕΣΤΗΜΕΝΩΝ ΙΜΙΔΑΖΟ[1,2-b]ΠΥΡΙΔΑΖΙΝΩΝ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ TRK | |
CY1111996T1 (el) | Παραγωγα πυρρολο[2,3-β]πυριδινης ως αναστολεις κινασης πρωτεϊνης | |
CY1122115T1 (el) | Παραγωγα ν1-ακυλο-5-φθοροπυριμιδινονης | |
EA201492165A1 (ru) | Синтез пирроло[2,3-b]пиридинов |